title: Obesity and its impact on breast cancer: tumor incidence, recurrence, survival, and possible interventions.
abstract: A positive association between obesity and the risk of incident postmenopausal breast cancer has been consistently observed in epidemiologic studies. Although most studies of premenopausal women have not found a similar relationship between breast cancer and obesity, the prognosis for both pre- and postmenopausal breast cancer is substantially worse among obese than normal-weight individuals. Increasing evidence suggests that these associations may be mechanistically related to sex hormones, insulin, and certain adipokines. Insulin, for example, has important mitogenic/antiapoptotic activity in addition to its metabolic effects, and many breast tumors express high levels of the insulin receptor (IR)-A isoform. Further, the use of metformin, a diabetes medication that reduces insulin levels, has been epidemiologically associated with reduced breast cancer risk among patients with diabetes, and a recent observational study found a higher rate of pathologic complete responses among patients with diabetes and breast cancer who were using metformin. Formal clinical trials of metformin as adjuvant breast cancer therapy have been initiated and are ongoing. Similarly, the effect of lifestyle changes on breast cancer outcomes is actively being investigated. Several lifestyle intervention studies have demonstrated that weight loss, increased physical activity, and dietary changes are feasible in breast cancer populations, and that individuals who make lifestyle changes after breast cancer diagnosis experience several physical and psychologic benefits. In this article, the authors review the evidence linking obesity with breast cancer risk and outcomes and provide an overview of lifestyle intervention studies in patients with breast cancer.
authors.affiliation: From the Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA; the Department of Epidemiology & Population Health, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY.
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Ligibel
authors.forename: Howard D
authors.initials: HD
authors.lastname: Strickler
mesh_terms: D001943:Breast Neoplasms / Q000453:epidemiology* / Q000401:mortality / Q000628:therapy; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000453:epidemiology; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008687:Metformin / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D009765:Obesity / Q000453:epidemiology*; D011379:Prognosis; D011972:Receptor, Insulin / Q000378:metabolism; D040242:Risk Reduction Behavior
chemical_list: D007004:Hypoglycemic Agents; D008687:Metformin; D011972:Receptor, Insulin